DREAMM-1 study in blood cancer furthering GSK's dreams in oncology

UK pharma major GlaxoSmithKline (LSE: GSK) on Thursday announced further positive data from the DREAMM-1 study of patients with relapsed/refractory multiple myeloma who received GSK2857916, an investigational anti-B-cell maturation antigen (BCMA) antibody-drug conjugate.

These results, published in Blood Cancer Journal ( link) build on those from the pre-specified interim analysis that were first presented at the American Society of Hematology Congress in 2017, and provide a further boost for GSK’s oncology research. GSK’s shares moved up 2.72% to 1,566.00 pence as markets were closing yesterday.

These new data confirm that 60% of patients receiving GSK2857916 achieved an overall response rate (ORR). This ORR was identical to the rate previously reported in the interim analysis, after more than a year of follow-up, and demonstrates not only the potential efficacy of the medicine but the durability and depth of response. The number of patients achieving a complete response increased to 15% over this additional one year follow-up period. The median progression-free survival (PFS) was 12 months (95% CI [3.1-Not Estimable/NE]), an increase from the previously reported 7.9 months PFS. The median duration of response in the final analysis was 14.3 months (95% CI [10.6-NE]). All patients whose data were reported in the interim analysis were included in this analysis.